


- Progress on Gavi 4.0
- Covid-19 response and risks
- Implications for Gavi 5.0
- Decisions



Anuradha Gupta – 24 June 2020, Geneva



2019 was a record year of performance, building further momentum on Gavi 4.0



¹ Share of countries meeting co-financing commitments on time; total amounts co-financed and self-financed by countries including India

² Cost of fully vaccinating a child with pentavalent, rotavirus and pneumococcal conjugate vaccine (PCV)

In 2020, Covid-19 is setting us back amid unprecedented uncertainty



In Gavi countries:


- Sharp increase in Covid-19 cases
- Countries in a state of flux
- Massive economic and fiscal impact
- Immunisation most disrupted among essential health services
- Inequities exacerbated



Imminent risks:

- Stress on domestic financing for vaccines and service delivery
- Drop in coverage
- Increased outbreaks
- More zero-dose children
- More child deaths in poor households

Gavi acted swiftly to help countries in their immediate response to the pandemic

- Reprogramming of HSS **up to 10%**
 - Repurposing of **partners' support** under PEF TCA
 - **Freezing** of eligibility status and co-financing at 2020 level
 - **Fast-tracked** approvals
 - **Regular dialogue** and information sharing **across the Alliance**
- 
- **\$76m** of support approved in 43 countries
 - **54%** used for IPC and PPE
 - **Procurement** of PPE through UNICEF
 - **Alignment** with national Covid-19 plans
 - **Coordination** with other financiers

Maintaining and restoring immunisation now a priority: Opportunity to rebuild better

- Enhanced focus on **equity and gender** in immunisation
- Catching up missed children through **tailored, integrated, efficient** approaches
- Tackling growing **vaccine hesitancy** and **rumors**
- Re-imagining **surveillance**
- Promoting **innovation**
- Broadening **partnerships**



While Gavi 5.0 is more relevant than ever, a few priorities and baseline would shift

Gavi, the Vaccine Alliance: 2021–2025 Strategy

Leaving no one behind with immunisation	
Mission 2025 To save lives and protect people's health by increasing equitable and sustainable use of vaccines	Mission Indicators <ul style="list-style-type: none"> Child mortality reduction tbd Lives saved tbd Future DALYs averted tbd Equity indicator tbd People (male & female) vaccinated with Gavi support across the life course tbd People (male & female) vaccinated with Gavi support against outbreak-prone diseases tbd Economic benefits unlocked tbd
Principles <ul style="list-style-type: none"> Missed communities, first priority: Prioritise children missing out on vaccination, including among migrants, displaced and other vulnerable populations Gender-focussed: Identify and address gender-related barriers to promote immunisation equity Country-led, sustainable: Bolster country leadership to sustainably deliver and finance immunisation Community-owned: Ensure community trust and confidence in vaccines by engaging communities in planning, implementation and oversight of immunisation Differentiated: Target and tailor support to national and subnational needs, including fragile contexts 	<ul style="list-style-type: none"> Integrated: Strengthen immunisation as a foundation for integrated primary health care to reach unserved communities in support of universal health coverage Adaptive, resilient: Help countries leverage immunisation to address the challenges of global issues Innovative: Identify and leverage innovative products, practices and services to reach everyone with immunisation Collaborative, accountable: Collaborate across stakeholders to achieve the SDGs in a transparent, coordinated and accountable manner
Goals <ol style="list-style-type: none"> INTRODUCE AND SCALE UP VACCINES STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS 	
Objectives <ol style="list-style-type: none"> <ul style="list-style-type: none"> A Strengthen countries' prioritisation of vaccines appropriate to their context B Support countries to introduce and scale up coverage of vaccines for prevention of endemic and epidemic diseases C Enhance outbreak response through availability and strategic allocation of vaccine stockpiles <ul style="list-style-type: none"> A Help countries extend immunisation services to regularly reach under-immunised and zero-dose children to build a stronger primary health care platform B Support countries to ensure immunisation services are well-managed, sustainable, harness innovation and meet the needs of all caregivers C Work with countries and communities to build resilient demand, and to identify and address gender-related barriers to immunisation <ul style="list-style-type: none"> A Strengthen national and subnational political and social commitment to immunisation B Promote domestic public resources for immunisation and primary health care to improve allocative efficiency C Prepare and engage self-financing countries to maintain or increase performance <ul style="list-style-type: none"> A Ensure sustainable, healthy market dynamics for vaccines and immunisation-related products at affordable prices B Incentivise innovation for the development of suitable vaccines C Scale up innovative immunisation-related products 	
Enablers <ul style="list-style-type: none"> Secure long-term predictable funding for Gavi programmes Ensure global political commitment for immunisation, prevention and primary health care Use evidence, evaluations and improved data for policies, programmes and accountability Leverage the private sector, including through innovative finance mechanisms and partnerships 	

Baseline and targets contingent on pandemic duration and scale of disruption

Equitable access and delivery of Covid 19 vaccines

Deferring VIS implementation

Recalibrating expectations on domestic financing for immunisation and sustained performance in former Gavi countries

Covid-19 has impacted timelines of Funding Policy Review

- **Funding Policy review** paused on recommendation of Steering Committee
- Recognition of the **changing context** and **limited country capacity** to implement new policies
- Proposal to **roll-out only select funding policy shifts** already approved by the Board in December 2019
- **Policy review to resume** when countries are preparing to move to a steadier state: Board to be updated in December 2020

Gavi's approach to MICs being adapted in the light of Covid-19

- **Comprehensive approach to MICs paused because of Covid-19**
- **Former Gavi countries face increased risk of backsliding**
 - current post-transition engagement is till 2020 only, limited to TA
- **Proposal to allocate up to \$20m for former Gavi countries in 2020- 2021**
 - excludes vaccines but goes beyond TA
- **Covax offers opportunity to engage with never Gavi-eligible MICs and lay the foundation for broader engagement**

Discussion topics:

- Progress on Gavi 4.0
- Covid-19 response and risks
- Implications for Gavi 5.0
- Decisions



THANK YOU
